Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 7.4% – Here’s What Happened

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) traded down 7.4% on Thursday. The stock traded as low as $11.34 and last traded at $11.1190. 251,251 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 585,250 shares. The stock had previously closed at $12.01.

Analyst Upgrades and Downgrades

DRTS has been the topic of several research analyst reports. Piper Sandler raised Alpha Tau Medical from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $8.00 to $22.00 in a research report on Wednesday, November 11th. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Barclays upped their price target on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, September 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Thursday, October 15th. Finally, UBS Group reiterated a “buy” rating on shares of Alpha Tau Medical in a report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.20.

Check Out Our Latest Research Report on DRTS

Alpha Tau Medical Stock Down 5.8%

The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $13.90 and a 200-day moving average price of $10.99. The firm has a market cap of $1.02 billion, a P/E ratio of -10.85 and a beta of 1.28.

Insiders Place Their Bets

In other Alpha Tau Medical news, CFO Raphi Levy sold 2,871 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at $1,352,700. This represents a 3.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alpha Tau Medical

Several hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC bought a new position in shares of Alpha Tau Medical during the first quarter valued at approximately $286,000. Principal Financial Group Inc. bought a new stake in Alpha Tau Medical during the 1st quarter valued at $132,000. Finally, Everhart Financial Group Inc. bought a new stake in Alpha Tau Medical during the 2nd quarter valued at $126,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.

See Also

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.